Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

被引：0
|
作者：
Laurie E. McLouth
Yue Zheng
Stephanie Smith
F. Stephen Hodi
Uma N. Rao
Gary I. Cohen
Thomas T. Amatruda
Shaker R. Dakhil
Brendan D. Curti
Ibrahim Nakhoul
Sreenivasa R. Chandana
Charles L. Bane
David E. Marinier
Sandra J. Lee
Vernon K. Sondak
John M. Kirkwood
Ahmad A. Tarhini
Lynne I. Wagner
机构：
[1] University of Kentucky,Department of Behavioral Science, College of Medicine, Markey Cancer Center
[2] Dana-Farber Cancer Institute—ECOG-ACRIN Biostatistics Center,Nancy N. and J.C. Lewis Cancer and Research Pavilion
[3] St. Joseph’s/Candler,undefined
[4] Dana-Farber Cancer Institute/Harvard Cancer Center,undefined
[5] University of Pittsburgh Cancer Institute,undefined
[6] Greater Baltimore Medical Center,undefined
[7] Minnesota Oncology,undefined
[8] Ascension Via Christi Hospitals,undefined
[9] Earle A. Chiles Research Institute,undefined
[10] Providence Cancer Institute,undefined
[11] Regional Cancer Center at Indian Path Community Hospital,undefined
[12] Cancer and Hematology Centers of Western Michigan/Cancer Research Consortium of West Michigan NCORP,undefined
[13] Good Samaritan Hospital-Dayton,undefined
[14] Gundersen Health System,undefined
[15] Moffitt Cancer Center,undefined
[16] Atrium Health Wake Forest Baptist Comprehensive Cancer Center,undefined
来源：
Quality of Life Research | 2023年 / 32卷
关键词：
Ipilimumab; Melanoma; Adjuvant therapy; Interferon; Patient-reported outcomes; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：183 / 196
页数：13
相关论文
共 50 条
  • [41] A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.
    Si, Lu
    Wang, Xuan
    Kong, Yan
    Lian, Bin
    Chi, Zhi Hong
    Cui, Chuan Liang
    Sheng, Xi Nan
    Mao, Li Li
    Tang, Bi Xia
    Li, Si Ming
    Yan, Qiao Xie
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Immunomodulatory effects of high-dose and lowdose interferon α2b in patients with high-risk resected melanoma -: The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690
    Kirkwood, JM
    Richards, T
    Zarour, HM
    Sosman, J
    Ernstoff, M
    Whiteside, TL
    Ibrahim, J
    Blum, R
    Wieand, S
    Mascari, R
    CANCER, 2002, 95 (05) : 1101 - 1112
  • [43] Toxicity of adjuvant treatment with high-dose interferon alpha 2b (HD-IFN) in high-risk stage III melanoma patients (pts): The Italian experience.
    Romanini, A
    Sarti, S
    Murr, R
    Doria, S
    Rondini, M
    Orlandini, C
    Menichetti, T
    Pigozzo, J
    Chiarion-Sileni, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 727S - 727S
  • [44] Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node-Negative Melanoma
    Hauschild, Axel
    Weichenthal, Michael
    Rass, Knuth
    Linse, Ruthild
    Ulrich, Jens
    Stadler, Rudolf
    Volkenandt, Matthias
    Grabbe, Stephan
    Proske, Ulrike
    Schadendorf, Dirk
    Brockmeyer, Norbert
    Vogt, Thomas
    Rompel, Rainer
    Kaufmann, Roland
    Kaatz, Martin
    Naeher, Helmut
    Mohr, Peter
    Eigentler, Thomas
    Livingstone, Elisabeth
    Garbe, Claus
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3496 - 3502
  • [45] Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma.
    Hansson, J.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Nilsson, B.
    Stierner, U. K.
    von der Maase, H.
    Brandberg, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]
    Chiarion-Sileni, V.
    Guida, M.
    Romanini, A.
    Ridolfi, R.
    Mandala, M.
    Del Bianco, P.
    Silvestri, B.
    Medici, M.
    Michiara, M.
    Dalla Palma, M.
    Puccetti, O.
    Pigozzo, J.
    Laveder, F.
    De Salvo, G. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence
    Kim, Kevin B.
    Legha, Sewa S.
    Gonzalez, Rene
    Anderson, Clay M.
    Johnson, Marcella M.
    Liu, Ping
    Papadopoulos, Nicholas E.
    Eton, Omar
    Plager, Carl
    Buzaid, Antonio C.
    Prieto, Victor G.
    Hwu, Wen-Jen
    Frost, Angela M.
    Alvarado, Gladys
    Hwu, Patrick
    Ross, Merrick I.
    Gershenwald, Jeffrey E.
    Lee, Jeffrey E.
    Mansfield, Paul F.
    Benjamin, Robert S.
    Bedikian, Agop Y.
    MELANOMA RESEARCH, 2009, 19 (01) : 42 - 49
  • [48] Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial
    Eggermont, A. M. M.
    Suciu, S.
    Santinami, M.
    Testori, A.
    Kruit, W.
    Marsden, J.
    Punt, C. J. A.
    Sales, F.
    Gore, M.
    Mckie, R.
    Kusic, V.
    Dummer, R.
    Musat, E.
    Spatz, A.
    Keilholz, U.
    PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 290 - 290
  • [49] Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis
    Hauschild, A
    Weichenthal, M
    Balda, BR
    Becker, JC
    Wolff, HH
    Tilgen, W
    Schulte, KW
    Ring, J
    Schadendorf, D
    Lischner, S
    Burg, G
    Dummer, R
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2883 - 2888
  • [50] Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma
    Lian, Bin
    Cui, Chuanliang
    Song, Xin
    Zhang, Xiaoshi
    Wu, Di
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Kong, Yan
    Mao, Li Li
    Zhou, Li
    Wang, Xuan
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Li, Dan
    Dai, Jie
    Bai, Xue
    Li, CaiLi
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345